Document is current
Any future updates will be listed below
-
Authors
Sidana, Surbhi https://orcid.org/0000-0003-3288-7614
Milani, Paolo
Binder, Moritz https://orcid.org/0000-0001-9014-9658
Basset, Marco
Tandon, Nidhi
Foli, Andrea
Dispenzieri, Angela
Gertz, Morie A.
Hayman, Suzanne R.
Buadi, Francis K.
Lacy, Martha Q.
Kapoor, Prashant
Leung, Nelson https://orcid.org/0000-0002-5651-1411
Rajkumar, S. Vincent https://orcid.org/0000-0002-5862-1833
Merlini, Giampaolo
Palladini, Giovanni
Kumar, Shaji K. https://orcid.org/0000-0001-5392-9284
-
Funding
Funding for this research was provided by:
Amyloidosis Foundation
- License Information
-
More Information
Article History
Received: 30 August 2019
Revised: 9 March 2020
Accepted: 19 March 2020
First Online: 14 April 2020
Conflict of interest
: S.S.: Honoraria/consultancy: Janssen; P.M.: Honoraria/consultancy: Janssen and Pfizer. P.M. is partly supported by a fellowship grant from Collegio Ghislieri (Pavia); A.D.: Consultant for Takeda; Research funding from Celgene, Takeda, Janssen; GlaxoSmithKline, Alnylam, and Pfizer; M.A.G.: Honoraria/consultancy from Ionis, Alnylam, Prothena, Celgene, Janssen, Specytrum, Annexon, Apellis, Amgen, Medscape, Abbvie, Research to Practice, Physcians Education Resource and Teva; P.K.: Research funding (Takeda, Celgene and Amgen); N.L.: Consultancy (Prothena); G.P.: Honoraria/consultancy: Celgene, Janssen, Prothena, Sebia; S.K.K.: Research Funding and membership on an entity’s Board of Directors or advisory committees: AbbVie, Celgene, Janssen KITE, Merck. Membership on an entity’s Board of Directors or advisory committees: Oncopeptides, Takeda. Research funding from Novartis and Roche; Remaining authors: none.
